May 28- A U.S. district court has ruled that Amarin Corp's fish oil pill, Vascepa, is eligible for five years of marketing exclusivity, setting aside a U.S. Food and Drug administration decision. Amarin's shares rose as much as 44 percent to $2.80 on the Nasdaq. The case is Amarin v.

May 7- Amarin Corp Plc filed suit against the U.S. Food and Drug Administration on Thursday for restricting its right to promote its fish oil drug Vascepa for an unapproved, or off-label, use. The suit, filed on Thursday in U.S. District Court for the Southern District of New York, argues that the FDA's ban violates Amarin's right to free speech under the First...

NEW YORK-- Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and Nasdaq Stock Market:. A Citi analyst maintained his "Buy" rating on the homebuilder's stock and raised his price target to $25 from $19 on margins.